Post by PharmaShots

Aligos Therapeutics licenses pevifoscorvir sodium to Amoytop Biotech for Greater China, securing $25M upfront and up to $420M in milestones to advance treatment for Chronic Hepatitis B Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #aligostherapeutics #pevifoscorvirsodium #amoytopbiotech #licensingdeal #hbv #pharma #phaseii #supreme https://lnkd.in/gFRi2c74